- Home
- TXO vs CRON Comparison
TXO vs CRON Comparison
Compare TXO & CRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXO
- CRON
- Stock Information
- Founded
- TXO 2012
- CRON N/A
- Country
- TXO United States
- CRON Canada
- Employees
- TXO N/A
- CRON N/A
- Industry
- TXO Oil & Gas Production
- CRON Medicinal Chemicals and Botanical Products
- Sector
- TXO Energy
- CRON Health Care
- Exchange
- TXO Nasdaq
- CRON Nasdaq
- Market Cap
- TXO 788.6M
- CRON 736.2M
- IPO Year
- TXO 2023
- CRON N/A
- Fundamental
- Price
- TXO $15.12
- CRON $2.07
- Analyst Decision
- TXO
- CRON
- Analyst Count
- TXO 0
- CRON 0
- Target Price
- TXO N/A
- CRON N/A
- AVG Volume (30 Days)
- TXO 288.6K
- CRON 1.3M
- Earning Date
- TXO 08-05-2025
- CRON 08-07-2025
- Dividend Yield
- TXO 15.91%
- CRON N/A
- EPS Growth
- TXO N/A
- CRON N/A
- EPS
- TXO 0.40
- CRON 0.13
- Revenue
- TXO $299,696,000.00
- CRON $124,589,000.00
- Revenue This Year
- TXO $33.41
- CRON $25.49
- Revenue Next Year
- TXO $9.20
- CRON $7.45
- P/E Ratio
- TXO $37.55
- CRON $16.34
- Revenue Growth
- TXO 3.43
- CRON 33.92
- 52 Week Low
- TXO $14.78
- CRON $1.60
- 52 Week High
- TXO $21.40
- CRON $2.54
- Technical
- Relative Strength Index (RSI)
- TXO 44.14
- CRON 63.54
- Support Level
- TXO $14.90
- CRON $1.87
- Resistance Level
- TXO $15.53
- CRON $2.15
- Average True Range (ATR)
- TXO 0.33
- CRON 0.06
- MACD
- TXO 0.00
- CRON 0.02
- Stochastic Oscillator
- TXO 20.00
- CRON 71.33
About TXO TXO Partners L.P.
TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America.
About CRON Cronos Group Inc. Common Share
Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.